Caprelsa for Medullary thyroid cancer
Quick answer: Caprelsa is used for Medullary thyroid cancer as part of a tyrosine kinase inhibitor treatment regimen. Inhibits RET, VEGFR, and EGFR tyrosine kinases blocking tumor angiogenesis and proliferation (vandetanib) The specific dosing for Medullary thyroid cancer is determined by your prescriber based on individual factors.
Why is Caprelsa used for Medullary thyroid cancer?
Caprelsa belongs to the Tyrosine kinase inhibitor class. Inhibits RET, VEGFR, and EGFR tyrosine kinases blocking tumor angiogenesis and proliferation (vandetanib) This action makes it useful for treating or managing Medullary thyroid cancer in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Caprelsa is the right choice for a specific patient depends on the type and severity of Medullary thyroid cancer, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Medullary thyroid cancer
Common adult dosing range: 300 mg once daily. The actual dose for Medullary thyroid cancer depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Caprelsa medicine page.
What to expect
Caprelsa treatment for Medullary thyroid cancer typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Medullary thyroid cancer
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Caprelsa is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Tyrosine kinase inhibitor for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Caprelsa
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Caprelsa full prescribing information · All Tyrosine kinase inhibitor alternatives
Frequently asked questions
How effective is Caprelsa for Medullary thyroid cancer?
Effectiveness varies by individual response, dose, and severity. Caprelsa is one of several treatment options for Medullary thyroid cancer, supported by clinical evidence within the tyrosine kinase inhibitor class. Discuss expected response with your prescriber.
How long do I need to take Caprelsa for Medullary thyroid cancer?
Treatment duration depends on the nature of Medullary thyroid cancer — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Caprelsa when used for Medullary thyroid cancer?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Caprelsa for Medullary thyroid cancer?
Yes. Multiple medicines and non-drug options exist for Medullary thyroid cancer. Alternatives within the tyrosine kinase inhibitor class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.